Summary of Significant Accounting Policies (Details) - USD ($) |
12 Months Ended | |||
|---|---|---|---|---|
Jul. 23, 2020 |
Dec. 31, 2022 |
Feb. 28, 2022 |
Dec. 31, 2021 |
|
| Summary Of Significant Accounting Policies | ||||
| Cash balance of insured FDIC amount | $ 1,600,000 | |||
| Cash balance of uninsured amount | $ 37,500,000 | |||
| Lease term | 2 years | |||
| Total future expense relating to the lease | $ 50,000 | |||
| Capitalized research and development services | 0 | $ 0 | ||
| Net operating loss carryforwards | 89,000,000 | |||
| Deferred tax asset, net operating loss carryforwards | 26,300,000 | |||
| Grants receivable | $ 0 | $ 1,100,000 | ||
| Maximum | ||||
| Summary Of Significant Accounting Policies | ||||
| Estimated useful life (years) | 10 years | |||
| Minimum | ||||
| Summary Of Significant Accounting Policies | ||||
| Estimated useful life (years) | 3 years | |||
| National Institutes of Health | 2020 Services Agreement | ||||
| Summary Of Significant Accounting Policies | ||||
| Amount of award received | $ 2,700,000 | $ 2,700,000 | ||
| Funding received in first year | $ 2,600,000 | |||
| Funding receivable in second year | $ 100,000 |